Colrain Capital’s Bristol-Myers Squibb BMY Stock Holding History

Colrain Capital’s Portfolio BMY Stock Details BMY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$12.3M	Buy	202,445 +50,745	+33%	+$2.96M	4.75%	10
2025 Q4	$8.18M	Sell	151,700 -26,325	-15%	-$1.27M	4.5%	10
2025 Q3	$8.03M	Buy	178,025 +54,025	+44%	+$2.52M	4.57%	9
2025 Q2	$5.74M	Sell	124,000 -9,000	-7%	-$442K	4.43%	9
2025 Q1	$8.11M	Buy	133,000 +11,500	+9%	+$670K	6.93%	5
2024 Q4	$6.87M	Buy	+121,500	New	+$6.79M	6.74%	5
2014 Q1	–	Sell	-1,000	Closed	-$53K	–	109
2013 Q4	$53K	Sell	1,000 -1,500	-60%	-$76.4K	﹤0.01%	105
2013 Q3	$116K	Sell	2,500 -1,000	-29%	-$43.9K	0.01%	99
2013 Q2	$156K	Buy	+3,500	New	+$152K	0.01%	95

Other funds holding BMY

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Colrain Capital's BMY Position: Q1 2026 in Review

Colrain Capital increased its Bristol-Myers Squibb (BMY) stake by 33% in Q1 2026, buying an estimated $2.96M and bringing the position to 202,445 shares worth $12.3M. The position accounts for 4.75% of the portfolio, ranked #10.

Colrain Capital first reported a position in BMY in Q2 2013 and has held it in 9 quarters since. 2,518 funds tracked by Wall St. Rank hold BMY as of Q1 2026.

Colrain Capital held 202,445 shares of Bristol-Myers Squibb worth $12.3M as of Q1 2026.
Colrain Capital bought 50,745 Bristol-Myers Squibb shares in Q1 2026, an estimated $2.96M.
Bristol-Myers Squibb made up 4.75% of Colrain Capital's portfolio in Q1 2026, its #10 holding.
Colrain Capital first reported a position in Bristol-Myers Squibb in Q2 2013 and has held it in 9 quarters since.
2,518 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q1 2026.

Based on Colrain Capital's 13F filing for Q1 2026, filed 12 May 2026.